Abstract
·Novel heterocyclic compound (EMBIA) was synthesized.·EMBIA-TiO2 and EMBIA-ZnO were successfully synthesized and characterized.·Anticancer and microbial activity EMBIA-TiO2 and EMBIA-ZnO were examined.·TGI of EMBIA and EMBIA-TiO2 (normal cell lines) were> 151.18µg/ml.
Ethyl-2-((5-methoxy-1H-benzo[d]imidazol-2-yl)thio)acetate (EMBIA) was synthesized by the reaction of ethylchloroacetate and 5-methoxy-2-mercaptobenzamidazole in the presence of potassium hydroxide. EMBIA was used to produce novel organic: inorganic nanohybrids with newly synthesized ZnO and TiO2 nanostructures and fully characterized using FTIR, SEM, EDX, XRD and TEM. Furthermore, the synthesized nanohybrids were used to check their antibacterial and antifungal activities against some normal and antibiotic resistance bacteria (E. faecalis VRE, E. faecalis, S. aureus, S. aureus MSSA, S. aureus MRSA, E. coli, E. coli ESBL, P. aeruginosa AGME, S. mutans, S. gordonii, A. actinomycetemcomitans) and fungi (C. albicans). Furthermore, these nanohybrids were used to check their anticancer activity against brain cancer cell lines, gynaecological cancer cell lines, colon cancer cell lines, in addition to lung, retinal, and skin normal cells were used to check the toxicity. The value of total growth inhibition (TGI) was 43.27 and 79.01 µg/ml for EMBIA and EMBIA-TiO2, while it was 4.29 µg/ml for the EMBIA-ZnO against normal cell lines. The TGI values against cancer cell lines of EMBIA and EMBIA-TiO2 were better than those reported for the reference compound 5-fluorouracil (5FU).